205 related articles for article (PubMed ID: 38473756)
1. Deep Flow Cytometry Unveils Distinct Immune Cell Subsets in Inducible T Cell Co-Stimulator Ligand (ICOSL)- and ICOS-Knockout Mice during Experimental Autoimmune Encephalomyelitis.
Raineri D; Abreu H; Vilardo B; Kustrimovic N; Venegoni C; Cappellano G; Chiocchetti A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473756
[TBL] [Abstract][Full Text] [Related]
2. [Dynamic alteration of CD154/CD40 and its effects on Th1/Th2 polarization in inducible co-stimulator ligand knockout mice infected with Schistosoma japonicum].
Wang Y; Xia CM
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 47(6):898-904. PubMed ID: 26679647
[TBL] [Abstract][Full Text] [Related]
3. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
Alves GF; Stoppa I; Aimaretti E; Monge C; Mastrocola R; Porchietto E; Einaudi G; Collotta D; Bertocchi I; Boggio E; Gigliotti CL; Clemente N; Aragno M; Fernandes D; Cifani C; Thiemermann C; Dianzani C; Dianzani U; Collino M
Front Immunol; 2022; 13():992614. PubMed ID: 36119089
[TBL] [Abstract][Full Text] [Related]
4. Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege.
Kunishige T; Taniguchi H; Terada M; Akiba H; Yagita H; Abe R; Hori J
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6815-6823. PubMed ID: 28002569
[TBL] [Abstract][Full Text] [Related]
5. Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production.
Maeda S; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K; Hasegawa M
Am J Pathol; 2011 Nov; 179(5):2360-9. PubMed ID: 21925472
[TBL] [Abstract][Full Text] [Related]
6. Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair.
Ramavath NN; Gadipudi LL; Provera A; Gigliotti LC; Boggio E; Bozzola C; Albano E; Dianzani U; Sutti S
Front Immunol; 2021; 12():786680. PubMed ID: 34925367
[TBL] [Abstract][Full Text] [Related]
7. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.
Hasegawa M; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K
Rheumatology (Oxford); 2013 Feb; 52(2):242-51. PubMed ID: 23024058
[TBL] [Abstract][Full Text] [Related]
8. ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis.
Galicia G; Kasran A; Uyttenhove C; De Swert K; Van Snick J; Ceuppens JL
J Clin Immunol; 2009 Jul; 29(4):426-33. PubMed ID: 19291374
[TBL] [Abstract][Full Text] [Related]
9. Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis.
Provera A; Ramavath NN; Gadipudi LL; Gigliotti CL; Boggio E; Vecchio C; Stoppa I; Rolla R; Boldorini R; Pirisi M; Smirne C; Albano E; Dianzani U; Sutti S
Front Immunol; 2023; 14():1290391. PubMed ID: 38077334
[TBL] [Abstract][Full Text] [Related]
10. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
[TBL] [Abstract][Full Text] [Related]
11. ADAM10-Mediated ICOS Ligand Shedding on B Cells Is Necessary for Proper T Cell ICOS Regulation and T Follicular Helper Responses.
Lownik JC; Luker AJ; Damle SR; Cooley LF; El Sayed R; Hutloff A; Pitzalis C; Martin RK; El Shikh MEM; Conrad DH
J Immunol; 2017 Oct; 199(7):2305-2315. PubMed ID: 28814605
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of ICOS ligand by interaction with ICOS functions as a regulatory mechanism for immune responses.
Watanabe M; Takagi Y; Kotani M; Hara Y; Inamine A; Hayashi K; Ogawa S; Takeda K; Tanabe K; Abe R
J Immunol; 2008 Apr; 180(8):5222-34. PubMed ID: 18390703
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
14. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway.
Tanaka C; Fujimoto M; Hamaguchi Y; Sato S; Takehara K; Hasegawa M
Arthritis Rheum; 2010 Jun; 62(6):1723-32. PubMed ID: 20191584
[TBL] [Abstract][Full Text] [Related]
15. ICOS regulates the generation and function of human CD4+ Treg in a CTLA-4 dependent manner.
Zheng J; Chan PL; Liu Y; Qin G; Xiang Z; Lam KT; Lewis DB; Lau YL; Tu W
PLoS One; 2013; 8(12):e82203. PubMed ID: 24312642
[TBL] [Abstract][Full Text] [Related]
16. ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo.
Stoppa I; Gigliotti CL; Clemente N; Pantham D; Dianzani C; Monge C; Puricelli C; Rolla R; Sutti S; Renò F; Boldorini R; Boggio E; Dianzani U
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806368
[TBL] [Abstract][Full Text] [Related]
17. Th17 down-regulation is involved in reduced progression of schistosomiasis fibrosis in ICOSL KO mice.
Wang B; Liang S; Wang Y; Zhu XQ; Gong W; Zhang HQ; Li Y; Xia CM
PLoS Negl Trop Dis; 2015 Jan; 9(1):e0003434. PubMed ID: 25590646
[TBL] [Abstract][Full Text] [Related]
18. ICOS/ICOSL upregulation mediates inflammatory response and endothelial dysfunction in type 2 diabetes mellitus.
Zhang HY; Ruan LB; Li Y; Yang TR; Liu WJ; Jiang YX; Li TR; Quan J; Xuan W
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8898-8908. PubMed ID: 30575933
[TBL] [Abstract][Full Text] [Related]
19. ICOS ligand and IL-10 synergize to promote host-microbiota mutualism.
Landuyt AE; Klocke BJ; Duck LW; Kemp KM; Muir RQ; Jennings MS; Blum SI; Tse HM; Lee G; Morrow CD; Elson CO; Maynard CL
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753483
[TBL] [Abstract][Full Text] [Related]
20. Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.
Le KS; Thibult ML; Just-Landi S; Pastor S; Gondois-Rey F; Granjeaud S; Broussais F; Bouabdallah R; Colisson R; Caux C; Ménétrier-Caux C; Leroux D; Xerri L; Olive D
Cancer Res; 2016 Aug; 76(16):4648-60. PubMed ID: 27246829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
